2Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa
*Corresponding Author: Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, and Department of Medicine, Johannesburg Academic Hospital and University of the Witwatersrand, michael.kew@uct.ac.za, South Africa. Tel: +27-217822949. Fax: +27-214486815. Email: michael.kew@uct.ac.za
How to Cite:Kew M. Hepatitis B Virus / Human Immunodeficiency Virus Co-Infection and Its Hepatocarcinogenic Potential in Sub-Saharan Black Africans. Hepat Mon. 2012;12(10):7876. doi: https://doi.org/10.5812/hepatmon.7876
Abstract
Context:
Since the introduction of highly active anti-retroviral regimen for human immunodeficiency virus-1 infection, a significant increase in the incidence of hepatocellular carcinoma has been reported in patients already chronically infected with hepatitis B virus and then given this form of regimen for their retroviral infection.
Evidence Acquisition:
This phenomenon was initially attributed to the far more prolonged survival of those patients who received this new regimen, which provided sufficient time, allowing hepatitis B virus-induced hepatocellular carcinoma to develop.
Results:
The current belief is that the increased incidence of hepatocellular carcinoma is because of co-infection with the two viruses, one known to be hepatocarcinogenic and the other suspected to increase the carcinogenic potential of the other. Because both hepatitis B virus and human immunodeficiency virus -1 are endemic in the Black population of sub-Saharan Africa and are transmitted in similar ways, as many as 20% of this population are co-infected with the two viruses. In this way, the already high risk of Black African patients developing hepatitis B virus-induced hepatocellular carcinoma is further increased.
Conclusions:
The pathogenetic mechanism or mechanisms involved in the carcinogenic interaction between the hepatitis B virus and the human immunodeficiency virus-1 in sub-Saharan Black Africans and other populations co-infected with these viruses have yet to be determined.
Ramezani A, Banifazl M, Mohraz M, Rasoolinejad M, Aghakhani A. Occult hepatitis B virus infection: A major concern in HIV-infected patients. Hepat Mon. 2011;11(1):. doi:
Li C, Che Y, Zhang Y, Xie N, Wang B, et al. Diagnosis and Treatment of Acute-on-Chronic Liver Failure Caused by HIV/HBV Co-infection: A Case Report. Hepat Mon. 2025;25(1):e154285. doi: https://doi.org/10.5812/hepatmon-154285
Karami C, H Adli A, Zhand S, Tabarraei A, Talei R, et al. Study of Genotype, Subtype and Mutation in the S Gene in Hepatitis B Patients Co-infected with HIV in Iran. Jundishapur J Microbiol. 2016;9(12):e34009. doi: https://doi.org/10.5812/jjm.34009
Senoglu S, Yesilbag Z, Kumbasar Karaosmanoglu H, Altuntas Aydin O. Prevalence of HBV/HCV Co-Infection and Associated Risk Factors in People Living with HIV. Hepat Mon. 2020;20(4):e98594. doi: https://doi.org/10.5812/hepatmon.98594